手术治疗HPV阴性口咽鳞状细胞癌的系统综述与Meta分析
该系统综述与Meta分析检索Pubmed、Web of Science和Cochrane数据库,纳入15项研究、共923例HPV阴性口咽鳞状细胞癌患者,评估以手术为基础的治疗结局。汇总2年和5年总生存率分别为84%和72%,单纯经口手术亚组分别为87%和82%。
要点
- HPV阴性口咽鳞状细胞癌手术联合病理指导的辅助治疗后,汇总2年总生存率为84%,5年总生存率为72%。
- 单纯经口手术亚组汇总2年总生存率为87%,5年总生存率为82%。
- 切缘阳性平均率为12.6%,接受风险分层辅助放疗平均率为30.7%,辅助放化疗平均率为29.5%。
核心结论
- HPV阴性口咽鳞状细胞癌患者接受任何手术方式联合病理指导的辅助治疗,2年和5年总生存率分别为84%和72%。
- 接受经口手术联合病理指导的辅助治疗的患者,2年和5年总生存率分别为87%和82%。
研究设计与样本
- 系统综述与Meta分析,按PRISMA声明报告,检索Pubmed、Web of Science和Cochrane数据库。
- 纳入15项研究进行定性合成,其中11项纳入Meta分析,共923例患者。
- 排除综述、评论、少于10例的病例系列以及包含混合部位HPV阴性头颈癌的研究。
主要发现
- 8项研究共483例报告了HPV阴性病变分期,其中81.6%为T1/T2肿瘤,41.4%为N0淋巴结病变。
- 切缘阳性平均率为12.6%,接受风险分层辅助放疗平均率为30.7%,辅助放化疗平均率为29.5%,平均随访32.7个月(SD=12.47个月)。
- 仅两项研究报告了按总体分期划分的HPV阴性病变生存结局:III期较IV期、早期较晚期病变的5年总生存率改善。
- 汇总2年和5年总生存率分别为84%(95%CI 77%-91%,I²=52.4%;5项研究)和72%(95%CI 46%-92%,I²=95.5%;4项研究)。
- 汇总2年和5年无病生存率分别为77%(95%CI 66%-86%,I²=55%;6项研究)和59%(95%CI 50%-69%,I²=0%;3项研究)。
局限性
- 原文在背景中指出,唯一探索该方法的随机试验(RTOG 1221)未能完成入组,原发性手术在HPV阴性口咽鳞状细胞癌治疗中的作用仍未得到解答。
- 5年总生存率汇总分析的异质性I²=95.5%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human papillomavirus (HPV) negative oropharyngeal squamous cell carcinoma (OPSCC) is associated with worse survival when compared to HPV-positive OPSCC. Primary surgery is one option to intensify therapy in this high-risk group of patients. Unfortunately, the only randomized trial to explore this approach (RTOG 1221) failed to accrue and the role of primary surgery in the treatment of HPV-negative OPSCC remains unanswered. METHODS: A systematic review and meta-analysis were performed to examine the outcomes of surgery in the treatment of HPV-negative OPSCC. We used the PRISMA statement for reporting and queried Pubmed, Web of Science and the Cochrane databases for studies examining the use of primary surgery in the treatment of HPV-negative OPSCC. Excluded from analysis were reviews, commentaries, case series with fewer than 10 patients, and studies that included HPV-negative head and neck cancers of mixed sites. Our primary outcomes were 2-year and 5-year overall survival (OS) and disease-free survival (DFS). OS and DFS were pooled using meta-analysis of proportions. RESULTS: A total of 15 studies were included in qualitative synthesis and 11 were included in the meta-analysis. There were 923 patients total included. Eight studies including 483 patients reported staging of HPV negative disease, of which 81.6% had T1/T2 tumors and 41.4% had N0 nodal disease. The average rate of positive margins was 12.6%. The average rate of patients who underwent risk-stratified adjuvant RT was 30.7% and CRT was 29.5%. The average follow-up was 32.7 months (SD = 12.47 months). Only two studies reported survival outcomes for HPV-negative disease based on overall staging: 5-year OS was improved for stage III versus stage IV and early versus late stage disease. The pooled 2- and 5-year OS were 84% (95% CI 77%-91%, I 2 = 52.4%; 5 studies) and 72% (95% CI 46%-92%, I 2 = 95.5%; 4 studies), respectively. The pooled 2- and 5-year DFS for the entire population were 77% (95% CI 66%-86%, I 2 = 55%; 6 studies) and 59% (95% CI 50%-69%, I 2 = 0%; 3 studies). Of the subgroup undergoing TOS alone, the pooled 2- and 5-year OS were 87% (95% CI 79%-93%, I 2 = 46.8%; 4 studies) and 82% (95% CI 69%-92%, I 2 = 74.2%; 3 studies). The pooled 2- and 5-year DFS for the subgroup of patients undergoing TOS alone were 78% (95% CI 63%-90%, I 2 = 56%; 4 studies) and 59% (95% CI 47%-71%, I 2 = undetermined; 2 studies). CONCLUSIONS: The two- and five-year OS for patients with HPV-negative OPSCC treated with any surgical approach and pathology-directed adjuvant therapy is 84% and 72%, respectively. The two- and five-year OS for HPV-negative OPCSCC treated with transoral surgery and pathology-directed adjuvant therapy is 87% and 82%, respectively.
引用
- McArdle E, Bulbul M, Collins C, et al. Surgery for the Treatment of HPV-Negative Oropharyngeal Squamous Cell Carcinoma-A Systematic Review and Meta-Analysis. Head Neck. 2025. PMID: 39866097. doi:10.1002/hed.28088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。